page

Our strategy

The COVID-19 pandemic has led us to refocus and refresh our strategy, but our purpose remains the same: giving every patient an empowered present and a hopeful future.

Our work in 2021 and beyond will deliver against four strategic cornerstones:

We will accelerate work on earlier detection and diagnosis to make the greatest impact on the length and quality of life for myeloma patients and those with related conditions.

  • The Myeloma UK Early Diagnosis programme identifies and addresses barriers to earlier diagnosis
  • The Myeloma UK Early Diagnosis Working Groups develop tools and education materials to speed up detection, referral and diagnosis at GP-level
  • We will establish the Myeloma UK Early Diagnosis Research programme to better understand how myeloma develops and identify patients at risk

We will drive scientific breakthrough into the cause and treatment of myeloma and related conditions to increase patient survival and improve patient experience.

  • Myeloma UK funds translational research at the ICR to accelerate the development of personalised medicine to myeloma patients
  • Myeloma UK funds the UKMRA Myeloma UK Concept & Access Research Programme (CARP) to create new clinical trials and give patients early access to novel treatments
  • Myeloma UK supports the development of future research leaders by funding a Clinical Research Fellowship at the University of Leeds and the development of our early care research programme, fostering interest in myeloma as a focus of future research
  • The Myeloma UK patient data project enables better insight and evidencing of patient need and changes to policy, treatment and care
  • Myeloma UK’s Health Service Research identifies unmet need and patient preferences to inform change in healthcare policy and delivery

We will partner with patients to understand and meet their needs and build equal care for all.

  • Myeloma UK puts patient need and experience at the heart of drug appraisals to make sure that patients can access new treatments
  • Myeloma UK drives excellence in patient-centred hospital care through our Clinical Services Excellence Programme (CSEP)
  • The Myeloma UK Myeloma Academy and Myeloma Nurse Learning Programme educate healthcare professionals to ensure that patients receive the best care informed by the latest learnings
  • Myeloma UK has the most comprehensive library of patient information on myeloma and related conditions, helping patients to understand and be in control of their decision-making
  • Myeloma UK offers specialist, tailored support to the whole myeloma community through our Myeloma Infoline and Ask the Nurse email service
  • Myeloma UK delivers a range of digital and physical events, directly connecting patients and families to expert analysis, advice and support
  • Myeloma UK partners patients to provide a UK-wide network of Support Groups, reducing isolation and offering friendship to the whole myeloma community
  • Myeloma UK will establish a volunteer peer to peer support service to bring together shared patient experiences and practical tips for living with myeloma and related conditions

We will give a voice to patients and ensure that myeloma is not considered a second-class cancer.

  • Myeloma UK works to shape government policy across the four UK nations to recognise the needs of patients with myeloma and related conditions and create positive change
  • The Myeloma UK Advocacy Panel ensures patients speak directly to decision makers in NICE and government
  • The Myeloma UK Patient and Carer Research Panel integrates patient need into research design and policy development
  • Myeloma UK’s Healthcare Advocacy Service programmes drive improvements in clinical practice and patient-centred care
  • Myeloma UK works with colleagues and stakeholders who share our vision for myeloma and blood cancer care and are committed to delivering positive change for patients